model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,FN,FN,NCT04323800,,False,0.0,,NCTId,protocolSection.identificationModule.nctId,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,Convalescent Plasma to Stem Coronavirus (CSSC-001),Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection,True,0.78,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial",True,0.96,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.,"This double-blinded, phase 2 randomized, controlled trial compared the efficacy and safety of prophylactic high titer (≥1:320) SARS-CoV-2 convalescent plasma (CCP) with standard plasma for preventing infection in exposed, uninfected individuals. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed COVID-19 in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The study hypothesized that CCP might prevent infection when administered before symptoms or laboratory evidence of infection. The primary outcome was development of SARS-CoV-2 infection.",True,0.9,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,TP,TP,"This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety of Anti- SARS-CoV-2 convalescent plasma as prophylaxis following exposure to COVID-19 (as defined in the inclusion criteria). Adults 18 years of age and older with high risk exposure as defined by CDC may participate. A total of 500 eligible subjects will be randomized in a 1:1 ratio to receive either high titer anti-SARS-CoV-2 plasma or control (SARS-CoV-2 non-immune plasma).","This randomized, double-blind, placebo-controlled clinical trial was conducted at 19 United States centers from June 2020 to March 2021 to compare the safety and efficacy of transfusion of CCP (intervention) with SARS-CoV-2 non-immune control plasma. A total of 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 were transfused. Two were excluded for SARS-CoV-2 RT-PCR positivity at screening.

Eligible subjects were randomized 1:1 to receive 1 unit of CCP or 1 unit of control plasma. CCP donors had a history of positive molecular assay test for SARS-CoV-2 infection and had SARS-CoV-2 antibody levels ≥1:320 titer by Euroimmun ELISA at screening. Control was standard SARS-CoV-2 non-immune plasma collected before January 1, 2020, or seronegative for SARS-CoV-2.

The primary efficacy outcome was incident SARS-CoV-2 infection by study day 28 by positive RT-PCR testing. Individuals were followed for 90 days with visits at days 0 (transfusion), 1, 3, 7, 14, 28, 60, and 90. Nasal swabs were collected at screening and at days 1, 7, 14, and 28. Secondary efficacy outcomes included disease severity measured to day 28 using a clinical event scale and efficacy examined based on donor antibody titer. Safety assessments included serious adverse events and transfusion reactions.

Of the 168 participants in the modified intention to treat analyses, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. There were 28 adverse events in CCP and 58 in control recipients. The restricted mean infection free time by 28 days for all SARS-CoV-2 infections (25.3 vs. 25.2 days; p=0.49) and COVID-19 (26.3 vs. 25.9 days; p=0.35) were similar for both groups. High titer CCP as post-exposure prophylaxis appeared safe, but did not prevent SARS-CoV-2 infection.",True,0.86,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,"['Coronavirus', 'Convalescence']","['COVID-19', 'SARS-CoV-2 infection', 'Coronavirus Disease 2019']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,TP,TP,['COVID-19'],"['SARS-CoV-2', 'COVID-19', 'Convalescent plasma', 'Post-exposure prophylaxis', 'Passive immunotherapy', 'High titer plasma', 'Prevention', 'Close contact exposure', 'Prophylaxis']",True,1.0,superset,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,TP,TP,['PHASE2'],['PHASE2'],True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,TP,TP,RANDOMIZED,RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,TRIPLE,DOUBLE,True,0.7,success,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,EV,EV,,"CCP and control plasma were in standard plasma bags, with identical labels. An independent safety monitor, masked to randomized assignment, reviewed all AEs, SAEs and changes in baseline safety laboratory values.",,,,DesignMaskingDescription,protocolSection.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.whoMasked,TP,FP,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']","['PARTICIPANT', 'INVESTIGATOR']",False,0.6666666666666666,partial,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,TP,TP,180,180,True,1.0,exact,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[1].measure,EV,EV,,COVID-19 (symptomatic infection),,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[2].measure,EV,EV,,Relationship between donor antibody titer and infection,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[1].description,EV,EV,,"Development of symptomatic SARS-CoV-2 infection (COVID-19) assessed at screening, transfusion (day 0), and days 1, 3, 7, 14, 28, and 60",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[2].description,EV,EV,,"Efficacy for preventing SARS-CoV-2 infection and COVID-19 examined based on donor antibody titer through characterization of donor IgG, including end point titers and area under the curve (AUC) using a standardized ELISA to measure IgG against the spike and receptor binding proteins and anti-SARS-CoV-2 IgG against recombinant S1 domain of the SARS-CoV-2 spike protein",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[1].timeFrame,EV,EV,,By day 28 post-transfusion,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[2].timeFrame,EV,EV,,By day 28 post-transfusion,,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].measure,EV,EV,,Safety assessments - Adverse events,,,,OtherOutcomeMeasure,protocolSection.outcomesModule.otherOutcomes.measure,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].description,EV,EV,,"Reportable adverse events (AEs) including serious AEs (SAEs) and transfusion reactions. Rates of severe transfusion reactions, AEs, grade 3 or 4 AEs, and death were evaluated by treatment arm.",,,,OtherOutcomeDescription,protocolSection.outcomesModule.otherOutcomes.description,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.otherOutcomes[0].timeFrame,EV,EV,,Through 90 days post-transfusion,,,,OtherOutcomeTimeFrame,protocolSection.outcomesModule.otherOutcomes.timeFrame,True,False,True,True,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"Inclusion Criteria

1. Subjects must be 18 years of age or older
2. Close contact exposure (as defined by CDC guidelines) to person with COVID-19 within 96 hours of randomization (and 120 hours of receipt of plasma)

Exclusion Criteria

1. Receipt of any blood product in past 120 days.
2. Medical, psychiatric,cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance.
3. Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of breath) at time of screening.
4. Laboratory evidence of COVID-19 infection at time of screening.
5. History or known laboratory evidence of previous COVID-19 infection.
6. History of prior reactions to transfusion blood products.
7. Inability to complete therapy with the study product within 24 hours after randomization.","Inclusion Criteria:
- Asymptomatic participants
- Aged ≥18 years
- Close contact exposure to a person with confirmed COVID-19 in the previous 120 hours
- Negative SARS-CoV-2 test within 24 hours before transfusion
- Met standard criteria for blood donation (for CCP donors)

Exclusion Criteria:
- SARS-CoV-2 vaccination
- Past or active SARS-CoV-2 infection
- SARS-CoV-2 RT-PCR positivity at screening
- Symptomatic at time of enrollment",True,0.78,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,True,True,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
